Organon & Co. Hits New 52-Week High at USD 13.48

Organon & Co., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.48 on June 11, 2026. This achievement marks a notable recovery from its 52-week low of USD 5.69, reflecting a substantial upward movement in the stock's performance. Despite the recent high, Organon & Co. has experienced a challenging year, with a performance decline of 35.06% compared to the S&P 500's gain of 22.78%. The company's market capitalization stands at USD 1,520 million, and it boasts a price-to-earnings (P/E) ratio of 3.00, indicating a potentially attractive valuation relative to its earnings. Additionally, Organon & Co. offers a dividend yield of 1.02%, which may appeal to income-focused investors. The company's return on equity is notably high at 69.90%, showcasing its efficiency in generating profits from shareholders' equity. With a debt-to-equity ratio of 10.78 and a price-to-book ratio of 2.02, Organon & Co. continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry.